His years of experience in the specialization of cancer therapies date back to 1988 when he joined the National Cancer Institute and the National Institutes of Health until 1991. He later spent six years at the Bristol-Myers Squibb Pharmaceutical Research Institute before he left to start the Seattle Genetics. Clay B. Siegall, Ph.D., is the CEO and Chairman of the Board. Seattle Genetics is an organization whose foundation is based on scientific innovation, arduous research, best drug development practices, and a passionate urge to help others.
The death of Dr. Siegall’s father with cancer inspired him to utilize the basic tools available to oncologists in finding better ways of helping cancer patients. After pursuing a doctorate at George Washington University and earning enough experience in three institutes that natured his passion for cancer therapy, he was well prepared to launch the Seattle Genetics Company. For over thirty years, he has been waking up daily excited and passionate about going around helping cancer patients.
Under the innovative leadership of Dr. Siegall, the FDA approved a collaborative effort by Takeda Pharmaceutical Company and Seattle Genetics for developing Antibody-Drug Conjugates (ADCs) in 2011 named ADCETRIS® (brentuximab vedotin). The drug has become an international brand. Seattle Genetics has made several advancements in creating ADCs that have proved vital in the fight against cancer.
Under his guidance, the organization has partnered with Genentech, AbbVie, and GlaxoSmithKline among other licenses in generating $300 million. Several ADCs are still utilizing the Seattle Genetics’ technology to experiment on other clinical developments. Through the Initial Public Offer (IPO) of 2001 and public financing, Dr. Siegall has enabled the organization to secure a capital of about $1.2 billion.
He is a member of the board of directors of various organizations such as the Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and the Washington Roundtable. He has also received various awards during his practice like the 2013 University of Maryland Alumnus of the Year for Computer and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. His skills have made a great impact in generating 15 patents and publishing 70 research reports.